Barinthus Biotherapeutics (BRNS) EBT (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly EBT came in at -$5.6 million in Q1 2026, up 71.8% YoY from -$3.2 million in Q1 2025, and up 50.27% on a QoQ basis from -$11.2 million in Q4 2025.
Barinthus Biotherapeutics (BRNS) EBT (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 7 years of EBT data on file, last reported at -$5.6 million in Q1 2026.
- Quarterly EBT rose 71.8% year-over-year to -$5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$52.5 million (up 19.66% YoY) and the FY2025 annual result came in at -$66.6 million, down 8.83% from the prior year.
- EBT rose to -$5.6 million in Q1 2026, from -$11.2 million in the prior quarter.
- In the past five years, EBT ranged from a high of $14.8 million in Q2 2022 to a low of -$25.0 million in Q2 2023.
- A 5-year average of -$12.3 million and a median of -$15.6 million in 2024 frame the typical range for EBT.
- Annual changes were most pronounced in 2022 — EBT surged 207.03% — and 2023, when it plunged 1195.21%.
- Tracing BRNS's EBT over 5 years: stood at -$23.2 million in 2022, then increased by 21.88% to -$18.1 million in 2023, then decreased by 13.68% to -$20.6 million in 2024, then jumped by 45.79% to -$11.2 million in 2025, then soared by 50.27% to -$5.6 million in 2026.
- The last three EBT figures came in at -$5.6 million (Q1 2026), -$11.2 million (Q4 2025), and -$14.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Barinthus Biotherapeutics | 25.01 Mn | 25.01 Mn | - | -10.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.62 Mn |
| Mar 31, 2026 | -5.55 Mn |
| Dec 31, 2025 | -11.16 Mn |
| Sep 30, 2025 | -14.64 Mn |
| Jun 30, 2025 | -21.15 Mn |
| Mar 31, 2025 | -19.68 Mn |
| Dec 31, 2024 | -20.59 Mn |
| Sep 30, 2024 | -8.13 Mn |
| Jun 30, 2024 | -16.95 Mn |
| Mar 31, 2024 | -15.56 Mn |
| Dec 31, 2023 | -18.11 Mn |
| Sep 30, 2023 | -14.71 Mn |
| Jun 30, 2023 | -24.96 Mn |
| Mar 31, 2023 | -18.74 Mn |
| Dec 31, 2022 | -23.18 Mn |
| Sep 30, 2022 | 7.55 Mn |
| Jun 30, 2022 | 14.77 Mn |
| Mar 31, 2022 | 1.71 Mn |
| Dec 31, 2021 | -16.67 Mn |
| Sep 30, 2021 | -7.05 Mn |